Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211


Overactivated neddylation pathway as a therapeutic target in lung cancer.

Li L, Wang M, Yu G, Chen P, Li H, Wei D, Zhu J, Xie L, Jia H, Shi J, Li C, Yao W, Wang Y, Gao Q, Jeong LS, Lee HW, Yu J, Hu F, Mei J, Wang P, Chu Y, Qi H, Yang M, Dong Z, Sun Y, Hoffman RM, Jia L.

J Natl Cancer Inst. 2014 May 22;106(6):dju083. doi: 10.1093/jnci/dju083. Print 2014 Jun.


Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.

Hua W, Li C, Yang Z, Li L, Jiang Y, Yu G, Zhu W, Liu Z, Duan S, Chu Y, Yang M, Zhang Y, Mao Y, Jia L.

Neuro Oncol. 2015 Oct;17(10):1333-43. doi: 10.1093/neuonc/nov066. Epub 2015 Apr 22.


Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.

Wang Y, Luo Z, Pan Y, Wang W, Zhou X, Jeong LS, Chu Y, Liu J, Jia L.

Cancer Biol Ther. 2015;16(3):420-9. doi: 10.1080/15384047.2014.1003003.


Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.

Lan H, Tang Z, Jin H, Sun Y.

Sci Rep. 2016 Apr 11;6:24218. doi: 10.1038/srep24218.


Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target.

Gao Q, Yu GY, Shi JY, Li LH, Zhang WJ, Wang ZC, Yang LX, Duan M, Zhao H, Wang XY, Zhou J, Qiu SJ, Jeong LS, Jia LJ, Fan J.

Oncotarget. 2014 Sep 15;5(17):7820-32.


Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.

Luo Z, Pan Y, Jeong LS, Liu J, Jia L.

Autophagy. 2012 Nov;8(11):1677-9. doi: 10.4161/auto.21484. Epub 2012 Aug 9.


Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Zhao Y, Morgan MA, Sun Y.

Antioxid Redox Signal. 2014 Dec 10;21(17):2383-400. doi: 10.1089/ars.2013.5795. Epub 2014 Feb 20. Review.


The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.

Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, Chu Y, Yi J, Wang X, Sun Y, Jeong LS, Liu J, Jia L.

Cancer Res. 2012 Jul 1;72(13):3360-71. doi: 10.1158/0008-5472.CAN-12-0388. Epub 2012 May 4.


Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Yao WT, Wu JF, Yu GY, Wang R, Wang K, Li LH, Chen P, Jiang YN, Cheng H, Lee HW, Yu J, Qi H, Yu XJ, Wang P, Chu YW, Yang M, Hua ZC, Ying HQ, Hoffman RM, Jeong LS, Jia LJ.

Cell Death Dis. 2014 Feb 13;5:e1059. doi: 10.1038/cddis.2014.21.


Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication.

Jiang Y, Jia L.

Anticancer Agents Med Chem. 2015;15(9):1127-33. Review.


MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Nawrocki ST, Griffin P, Kelly KR, Carew JS.

Expert Opin Investig Drugs. 2012 Oct;21(10):1563-73. Epub 2012 Jul 16. Review.


NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.

Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F.

Clin Cancer Res. 2015 Dec 15;21(24):5532-42. doi: 10.1158/1078-0432.CCR-15-0254. Epub 2015 Jul 8.


NEDD8-mediated neddylation is required for human endometrial stromal proliferation and decidualization.

Liao Y, Jiang Y, He H, Ni H, Tu Z, Zhang S, Wang B, Lou J, Quan S, Wang H.

Hum Reprod. 2015 Jul;30(7):1665-76. doi: 10.1093/humrep/dev117. Epub 2015 May 23.


Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.

Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES.

Cancer Res. 2013 Jan 1;73(1):225-34. doi: 10.1158/0008-5472.CAN-12-1729. Epub 2012 Oct 24.


Biochemical and cellular effects of inhibiting Nedd8 conjugation.

Leck YC, Choo YY, Tan CY, Smith PG, Hagen T.

Biochem Biophys Res Commun. 2010 Jul 30;398(3):588-93. doi: 10.1016/j.bbrc.2010.06.128. Epub 2010 Jul 13.


Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.

Pan WW, Zhou JJ, Yu C, Xu Y, Guo LJ, Zhang HY, Zhou D, Song FZ, Fan HY.

J Biol Chem. 2013 Oct 11;288(41):29680-91. doi: 10.1074/jbc.M113.495069. Epub 2013 Aug 30.


The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.

Yang D, Tan M, Wang G, Sun Y.

PLoS One. 2012;7(3):e34079. doi: 10.1371/journal.pone.0034079. Epub 2012 Mar 22.


Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.

Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li C, Zhang P, Wei D, Li P, Jeong LS, Chu Y, Qi H, Yang M, Hoffman RM, Dong Z, Jia L.

Oncotarget. 2015 Apr 20;6(11):9002-17.


Neddylation pathway regulates the proliferation and survival of macrophages.

Li L, Liu B, Dong T, Lee HW, Yu J, Zheng Y, Gao H, Zhang Y, Chu Y, Liu G, Niu W, Zheng S, Jeong LS, Jia L.

Biochem Biophys Res Commun. 2013 Mar 15;432(3):494-8. doi: 10.1016/j.bbrc.2013.02.028. Epub 2013 Feb 14.


Supplemental Content

Support Center